Asset Management Corp Intra Cellular Therapies, Inc. Transaction History

Asset Management Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 13, 2021	SELL	$28.72 - $42.49 $550,993 - $815,170	-19,185 Closed	0 $0
Q2 2021 Aug 06, 2021	SELL	$29.3 - $44.5 $73,250 - $111,250	-2,500 Reduced 11.53%	19,185 $783,000
Q1 2021 May 04, 2021	BUY	$30.8 - $39.51 $163,240 - $209,403	5,300 Added 32.35%	21,685 $736,000
Q4 2020 Jan 29, 2021	SELL	$23.34 - $32.22 $100,362 - $138,546	-4,300 Reduced 20.79%	16,385 $553,000
Q3 2020 Oct 26, 2020	BUY	$17.61 - $31.86 $48,427 - $87,615	2,750 Added 15.33%	20,685 $531,000
Q1 2020 Apr 14, 2020	BUY	$12.31 - $33.12 $9,909 - $26,661	805 Added 4.7%	17,935 $276,000
Q4 2019 Feb 04, 2020	BUY	$7.26 - $38.49 $124,363 - $659,333	17,130 New	17,130 $588,000

399

87.2M

309K

302K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $6.86B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Asset Management Corp , based on Form 13F filings with the SEC.

Stay updated on Asset Management Corp with notifications on news.